Frequently Asked Questions

F.A.Q:

Are your products legal in Canada?

Yes. Our ethnobotanical products are offered and sold in a manner that complies with Canadian law when not paired with medical claims or use-based representations. Ibogaine has been added to Canada's Prescription Drug List. This is a regulatory control mechanism. However, Ibogaine remains unscheduled in Canada's Controlled Drugs and Substances Act. 

In this way, unlicensed and unqualified treatment providers can be controlled, while possession, non-medical sale, and scientific research remain non-criminalized. It is for this reason why we establish clear boundaries for the intended use of our material.

Is this a medical or therapeutic service?

No. We supply ethnobotanical materials for laboratory use only. We do not provide medical advice, treatment, diagnosis, or health-related guidance.

Can you explain how to use these materials therapeutically?

No, we cannot provide guidance, advice, or discussion regarding preparation, consumption, dosing, therapeutic use, or any form of human consumption.

Requests of this nature — including attempts to solicit instructions, medical claims, or facilitation of use — are outside the scope of our business and may result in refusal of service or sale.

What are the intended uses of these materials?

Our ethnobotanical materials are intended solely for lawful scientific, laboratory, and research purposes. Typical applications include calibration and validation of analytical instruments (such as HPLC, LC-MS, or GC-MS), in-vitro experimental work, phytochemical characterization, method development, and academic or educational study of plant alkaloids. They are not intended for human consumption or any form of in-vivo application.

Medical interest in Ibogaine has grown substantially in recent years, while reference materials have remained largely inaccessible. By making this material available, we lower the barrier-to-entry for students, labs, and researchers, with the hope that this may accelerate the understanding and development of Ibogaine as a therapeutic medicine.

Are your products pharmaceutical grade?

No. "Pharmaceutical grade" Ibogaine as considered in Canada's Prescription Drug List is a highly purified material which is validated, intended, and approved for human consumption. Iboga and essential extracts for laboratory use, even if produced to a similar quality/purity standard, fall outside of this classification.

To comply with applicable regulation, our offerings are presented as "ethnobotanical materials/analytical samples", not pharmaceutical products, supplements, or medicines.

What are ethnobotanical materials?

Ethnobotanical materials are plant specimens and essential oils/extracts studied in historical, cultural, or academic contexts.

How do you source your materials?

We work directly with established suppliers and prioritize traceability, ethical sourcing, and consistency, where applicable and appropriate.

Do you test or analyze your products?

Yes, each batch of product is tested for purity via mass spectrometry. Where appropriate, limited documentation related to sourcing or handling may be available upon request. Availability varies by product.

What payment methods do you accept?

We offer the following payment options:

  • Interac e-Transfer: Instructions for completing your e-transfer will be provided at checkout.
  • Cryptocurrency (BTC): We accept Bitcoin (BTC), Payment instructions will be provided at checkout.

Are orders shipped domestically (within Canada)?

Yes. All orders will be shipped from within Canada, ensuring rapid delivery and privacy.

When / How frequently are orders shipped?

Orders placed by 2:00pm EST, Monday through Friday, will be shipped the same day.

How can I see shipping rates and options?

Enter your full shipping address during checkout to view available shipping rates and options. We offer standardized shipping through Canada Post and Purolator.

How discreet is your packaging?

Orders are shipped in plain, discreet packaging with no medical or misleading descriptions.

Will I receive a tracking number?

Yes, a tracking number is included in your order confirmation email. Note: It may take 6-24 hours for the tracking to become active on the Canada Post website.

Who is responsible for shipping delays?

Once your order is with the shipper, Canada Ibogaine Supply | Iboga Canada is not responsible for any delays. Canada Post may sometimes experience short delays.

What happens if my order doesn’t arrive?

All orders are guaranteed to arrive. If they don’t, we will reship your order.

Do you ship internationally?

At this time, we do not offer international shipping. Sales in CANADA Only

Do you accept bulk or wholesale inquiries?

Yes. Wholesale or bulk inquiries may be considered for credentialed researches and facilities, only if they align with our ethical & compliance requirements. Bulk orders will not be considered for private individuals.

Send details of your inquiry to: contact@canadaibogaine.ca

What if i have more questions?

Curious about our products or policies? Contact us for all the information you need. Use the "Contact Us" page, or send an email to: contact@canadaibogaine.ca

By continuing, you acknowledge that any academic documentation or informational material linked on this website is provided for scholarly curiosity only and does not reflect any recommended use of any product offered elsewhere on this site.

Research Hub

  • First Results of Low-Dose Ibogaine Research to Reverse Methadone Tolerance

    A study conducted in Catalonia by ICEERS and Sant Joan de Reus University Hospital has published preliminary results showing how the use of low-dose ibogaine can reduce methadone tolerance in patients with opioid dependence. All study participants were able to reduce their Methadone dosage by 50% following a single 100mg dose. This innovative clinical trial seeks to offer therapeutic alternatives to the opioid epidemic that affects millions of people worldwide.

    Read Full Text 

  • Detoxification from Methadone using low, repeated, and increasing doses of Ibogaine: A case report

    This peer-reviewed case report documents the first use of low, repeated, and escalating doses of ibogaine to detoxify a long-term methadone maintenance patient, demonstrating sustained suppression of withdrawal symptoms without clinically significant cardiac adverse effects, and continued methadone abstinence at 12-month follow-up.

    Read Full Text 

  • Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification - Potential Outpatient Microdosing Procedure

    This Phase II randomized clinical trial registered on ClinicalTrials.gov examines the efficacy and cardiac safety of ibogaine for methadone detoxification, comparing fixed, weekly microdoses with ascending-dose protocols administered during withdrawal-driven tapering in long-term maintenance patients.

    Read Full Text 

  • Remission of severe opioid use disorder with ibogaine: a case report

    This peer-reviewed case report describes a woman with severe, treatment-refractory opioid use disorder who achieved 18 months of sustained opioid abstinence following a short, high-dose four-day ibogaine treatment, after failing multiple conventional therapies including methadone maintenance. Published in the Journal of Psychoactive Drugs, the paper highlights both ibogaine’s potential to induce durable remission, and the importance of careful medical screening and cardiac risk management, while emphasizing the need for controlled clinical trials to establish safety and efficacy.

    Read Full Text 

  • Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets

    This Stanford Medicine article reports that ibogaine, given with cardiac protection, led to large and sustained reductions in PTSD, depression, anxiety, and functional disability in special-operations veterans with traumatic brain injury treated at a supervised clinic in Mexico. The findings, supported by brain-imaging data published in Nature Mental Health, suggest ibogaine may promote neuroplasticity and cognitive recovery, with no serious adverse cardiac events observed, supporting further clinical study.

    Read Full Text 

  • Case report: Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion

    Published in Frontiers in Pain Research, this case report describes a patient with severe, treatment-resistant neuropathic pain from brachial plexus nerve root avulsion who achieved substantial and lasting pain relief following ibogaine treatment after decades of failed therapies. Improvements were reflected across validated pain scales, sensory experience, and functional outcomes, suggesting ibogaine’s multimodal neurobiological actions may support its potential role in refractory neuropathic pain, beyond addiction treatment.

    Read Full Text 

  • Clinical Guidelines for Ibogaine-Assisted Detoxification - 1st Edition, Version 1.1

    This document outlines consensus-based clinical safety guidelines for high-dose ibogaine–assisted opioid detoxification, synthesizing decades of clinical experience and published research to standardize screening, dosing, cardiac monitoring, psychological risk management, and aftercare. It focuses on purified ibogaine hydrochloride, emphasizing QT-interval risk, drug interactions, patient selection, and supervised care environments, with the goal of reducing preventable adverse events and establishing minimum standards for clinical and research use.

    Read Full Text 

  • Manual for high-dose Ibogaine Therapy - Screening, Safety, Monitoring & Aftercare

    This document, The Ibogaine Dossier / Manual for Ibogaine Therapy, is an early consensus-based safety and treatment manual that synthesizes decades of clinical observation, provider experience, and selected NIDA draft protocols to establish practical guidelines for ibogaine-assisted addiction interruption. It focuses heavily on risk reduction — screening, cardiac and laboratory testing, dosing ranges, monitoring, and aftercare — while acknowledging diverse provider philosophies. Rather than promoting ibogaine as a cure, the manual frames it as a powerful but high-risk intervention .

    Read Full Text 

  • Notes for Ibogaine treatment providers

    This practitioner memoir documents real-world ibogaine treatment practice from a non-medical provider, emphasizing informed consent, strict cardiac and liver screening, careful dosing, constant supervision, and set-and-setting as central to safety. Drawing on firsthand cases, it highlights gender differences in response, risks from comorbid conditions, and the limits of ibogaine as a stand-alone intervention, arguing that post-treatment support, especially body-based therapies and peer connection, is critical for sustaining recovery and preventing relapse.

    Read Full Text 

Buy Ibogaine Online in Canada ｜ Canada Ibogaine For Sale
Welcome to the Canada Ibogaine Supply / Iboga Canada!
Canada's Safe & Accessible Provider of Ibogaine Research Samples

Our products are crafted with significant care, and a high attention to detail & purity.
All plant-sources are obtained ethically and sustainably, without wild-harvesting. 

Warning: This botanical material is not sold for human consumption. This product is intended solely for analytical use or in-vitro scientific research. Iboga alkaloids may pose significant risks if improperly used, including but not limited to cardiac toxicity, neuropsychiatric events, and interaction with medications. Individuals exploring the topic of Ibogaine ingestion are strongly urged to consult independent, third-party harm reduction resources. No guidance, dosing advice, or therapeutic claims are offered or implied by this platform.